Ronil A. Patel - 24 Apr 2023 Form 3 Insider Report for Ocuphire Pharma, Inc. (IRD)

Role
SVP, Operations & Bus. Dev.
Signature
/s/ Emily J. Johns, by Power of Attorney
Issuer symbol
IRD
Transactions as of
24 Apr 2023
Net transactions value
$0
Form type
3
Filing time
26 Apr 2023, 21:19:44 UTC
Next filing
05 Dec 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding OCUP Common Stock 22,304 24 Apr 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding OCUP Employee Stock Option (right to buy) 24 Apr 2023 Common Stock 18,000 $6.04 Direct F1
holding OCUP Employee Stock Option (right to buy) 24 Apr 2023 Common Stock 20,000 $5.37 Direct F2
holding OCUP Employee Stock Option (right to buy) 24 Apr 2023 Common Stock 18,800 $2.90 Direct F3
holding OCUP Employee Stock Option (right to buy) 24 Apr 2023 Common Stock 15,000 $2.24 Direct F4
holding OCUP Employee Stock Option (right to buy) 24 Apr 2023 Common Stock 25,956 $3.50 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests in twenty-four (24) equal monthly increments of 750 shares on the last day of each month from April 2021 through March 2023.
F2 5,000 shares vested on June 30, 2022, then 416 shares vest at the end of each month from July 2022 through May 2025, and 440 shares vest at the end of June 2025.
F3 The option vested with respect to 4,700 shares on January 28, 2023, and then with respect to 391 shares on the last day of each month from February 2023 through December 2025 and with respect to 415 shares at the end of January 2026.
F4 The option vests with respect to 3,750 shares on September 1, 2023, and then with respect to 312 shares on the last day of each month from September 2023 through July 2026 and with respect to 330 shares at the end of August 2026.
F5 25% of the shares subject to the option vest on the first anniversary of the grant date, with the balance vesting quarterly in 12 equal installments thereafter.

Remarks:

Exhibit 24, Power of Attorney, is attached.